{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:33:36Z","timestamp":1787168016772,"version":"build-2736575974"},"reference-count":41,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Extranodal natural killer\/T-cell lymphoma (ENKTL) is rare, and treatment options for relapsed\/refractory (R\/R) disease are limited. This multicenter, single-arm phase 2 study evaluated the efficacy and safety of atezolizumab monotherapy in patients with R\/R ENKTL. The primary end point was objective response rate (ORR), as assessed by an independent review committee (IRC). Fourteen patients were ultimately enrolled. Among the 13 with evaluable responses, the median age was 72 years (range, 27-80), 46% were female, and 77% had an Eastern Cooperative Oncology Group performance status of 1. The IRC-assessed ORR was 54% (7\/13), including 4 complete responses (31%). Over a median follow-up period of 24.9 months, the median duration of response was not reached. Median progression-free survival and overall survival were 2.4 and 10.3 months, respectively. Structural variations (SVs) in programmed cell death ligand 1 (PD-L1) were detected in 4 of 11 evaluable patients (36%) by targeted-capture sequencing and\/or fluorescence in situ hybridization. The ORR in those patients was 75% (3\/4), whereas 3 of 7 patients without PD-L1 SVs responded (ORR, 43%). PD-L1 expression was positive in 5 of 11 evaluable patients (45%) by immunohistochemistry. The ORR in that group was 80% (4\/5) vs 33% (2\/6) in those without PD-L1 expression. Atezolizumab demonstrated clinically meaningful efficacy with durable responses in patients with R\/R ENKTL. PD-L1 genetic alterations and\/or PD-L1 expression levels may represent predictive biomarkers of patient response to this approach. This trial was registered at the Japan Registry of Clinical Trials (jRCT2031190177).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026019929","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T20:54:52Z","timestamp":1779310492000},"page":"5276-5284","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Atezolizumab for relapsed\/refractory extranodal NK\/T-cell lymphoma: phase 2 of NCCH1903\/ATTACK trial"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6609-8088","authenticated-orcid":false,"given":"Shinichi","family":"Makita","sequence":"first","affiliation":[{"name":"1Department of Hematology, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0605-1226","authenticated-orcid":false,"given":"Junji","family":"Koya","sequence":"additional","affiliation":[{"name":"2Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan"},{"name":"3Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Suzuki","sequence":"additional","affiliation":[{"name":"4Department of Hematology, NHO Nagoya Medical Center, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4171-2162","authenticated-orcid":false,"given":"Momoko","family":"Nishikori","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2682-2179","authenticated-orcid":false,"given":"Noriko","family":"Fukuhara","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Tohoku University, Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7251-7920","authenticated-orcid":false,"given":"Akiko Miyagi","family":"Maeshima","sequence":"additional","affiliation":[{"name":"7Department of Pathology, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Hirakawa","sequence":"additional","affiliation":[{"name":"8Department of Clinical Biostatistics, Institute of Science Tokyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7259-4870","authenticated-orcid":false,"given":"Yuta","family":"Ito","sequence":"additional","affiliation":[{"name":"2Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1158-5131","authenticated-orcid":false,"given":"Yasunori","family":"Kogure","sequence":"additional","affiliation":[{"name":"2Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Chiba","sequence":"additional","affiliation":[{"name":"9Division of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Okada","sequence":"additional","affiliation":[{"name":"9Division of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Shiraishi","sequence":"additional","affiliation":[{"name":"9Division of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5289-5518","authenticated-orcid":false,"given":"Satoshi","family":"Kawashima","sequence":"additional","affiliation":[{"name":"10Clinical Research Support Office, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5481-8284","authenticated-orcid":false,"given":"Yukari","family":"Nagasaka","sequence":"additional","affiliation":[{"name":"10Clinical Research Support Office, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"11Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan"},{"name":"12Pathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Nagai","sequence":"additional","affiliation":[{"name":"4Department of Hematology, NHO Nagoya Medical Center, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1599-5800","authenticated-orcid":false,"given":"Kengo","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"11Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan"},{"name":"12Pathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan"},{"name":"13Department of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kataoka","sequence":"additional","affiliation":[{"name":"2Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan"},{"name":"3Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[{"name":"1Department of Hematology, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"issue":"2","key":"2026081110270967200_bib1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.hoc.2016.11.007","article-title":"Clinical features and current optimal management of natural killer\/T-cell lymphoma","volume":"31","author":"Makita","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"key":"2026081110270967200_bib2","author":"WHO Classification of Tumours","year":"2024","edition":"5th ed"},{"issue":"3","key":"2026081110270967200_bib3","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S1470-2045(15)00533-1","article-title":"A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis","volume":"17","author":"Kim","year":"2016","journal-title":"Lancet Oncol"},{"issue":"25","key":"2026081110270967200_bib4","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026081110270967200_bib5","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1182\/bloodadvances.2024014674","article-title":"Global outcomes and prognosis for relapsed\/refractory mature T-cell and NK-cell lymphomas: results from the PETAL Consortium","volume":"9","author":"Han","year":"2025","journal-title":"Blood Adv"},{"issue":"23","key":"2026081110270967200_bib6","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1182\/blood-2017-12-791418","article-title":"Advances in the treatment of extranodal NK\/T-cell lymphoma, nasal type","volume":"131","author":"Yamaguchi","year":"2018","journal-title":"Blood"},{"issue":"32","key":"2026081110270967200_bib7","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1200\/JCO.2012.45.6541","article-title":"Concurrent chemoradiotherapy for localized nasal natural killer\/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211","volume":"30","author":"Yamaguchi","year":"2012","journal-title":"J Clin Oncol"},{"issue":"33","key":"2026081110270967200_bib8","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1200\/JCO.2009.23.8295","article-title":"Phase I\/II study of concurrent chemoradiotherapy for localized nasal natural killer\/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211","volume":"27","author":"Yamaguchi","year":"2009","journal-title":"J Clin Oncol"},{"issue":"33","key":"2026081110270967200_bib9","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2011.35.6287","article-title":"Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study","volume":"29","author":"Yamaguchi","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026081110270967200_bib10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1200\/JCO.2016.68.1619","article-title":"Treatments and outcomes of patients with extranodal natural killer\/T-cell lymphoma diagnosed between 2000 and 2013: a cooperative study in Japan","volume":"35","author":"Yamaguchi","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026081110270967200_bib11","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1093\/annonc\/mdx316","article-title":"Beyond first-line non-anthracycline-based chemotherapy for extranodal NK\/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease","volume":"28","author":"Lim","year":"2017","journal-title":"Ann Oncol"},{"issue":"7","key":"2026081110270967200_bib12","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/s41375-019-0380-5","article-title":"Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas","volume":"33","author":"Kataoka","year":"2019","journal-title":"Leukemia"},{"issue":"13","key":"2026081110270967200_bib13","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1158\/0008-5472.CAN-24-0132","article-title":"Comprehensive genetic profiling reveals frequent alterations of driver genes on the X chromosome in extranodal NK\/T-cell lymphoma","volume":"84","author":"Ito","year":"2024","journal-title":"Cancer Res"},{"issue":"17","key":"2026081110270967200_bib14","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing L-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2026081110270967200_bib15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13045-018-0559-7","article-title":"Activity of pembrolizumab in relapsed\/refractory NK\/T-cell lymphoma","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"2","key":"2026081110270967200_bib16","doi-asserted-by":"crossref","first-page":"681","DOI":"10.4143\/crt.2023.1042","article-title":"Pembrolizumab for patients with relapsed or refractory extranodal NK\/T-cell lymphoma in Korea","volume":"56","author":"Lee","year":"2024","journal-title":"Cancer Res Treat"},{"issue":"1","key":"2026081110270967200_bib17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00277-017-3127-2","article-title":"PD1 blockade with low-dose nivolumab in NK\/T cell lymphoma failing L-asparaginase: efficacy and safety","volume":"97","author":"Chan","year":"2018","journal-title":"Ann Hematol"},{"issue":"1","key":"2026081110270967200_bib18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41392-021-00768-0","article-title":"Sintilimab for relapsed\/refractory extranodal NK\/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4)","volume":"6","author":"Tao","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"16","key":"2026081110270967200_bib19","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.22.02367","article-title":"Sugemalimab monotherapy for patients with relapsed or refractory extranodal natural killer\/T-cell lymphoma (GEMSTONE-201): results from a single-arm, multicenter, phase II study","volume":"41","author":"Huang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"24","key":"2026081110270967200_bib20","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1182\/blood.2020007247","article-title":"Avelumab for the treatment of relapsed or refractory extranodal NK\/T-cell lymphoma: an open-label phase 2 study","volume":"136","author":"Kim","year":"2020","journal-title":"Blood"},{"issue":"16","key":"2026081110270967200_bib21","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1182\/bloodadvances.2022009575","article-title":"Treating relapsed\/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study","volume":"7","author":"Bachy","year":"2023","journal-title":"Blood Adv"},{"issue":"27","key":"2026081110270967200_bib22","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026081110270967200_bib23","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2307\/2533377","article-title":"Practical Bayesian guidelines for phase IIB clinical trials","volume":"50","author":"Thall","year":"1994","journal-title":"Biometrics"},{"issue":"7607","key":"2026081110270967200_bib24","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature18294","article-title":"Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers","volume":"534","author":"Kataoka","year":"2016","journal-title":"Nature"},{"issue":"5","key":"2026081110270967200_bib25","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/PAS.0000000000002372","article-title":"High-accuracy detection of PD-L1 3'-UTR disruption by immunohistochemistry and fluorescence in situ hybridization on formalin-fixed paraffin-embedded sections","volume":"49","author":"Fujimoto","year":"2025","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"2026081110270967200_bib26","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1111\/cas.15427","article-title":"Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies","volume":"113","author":"Fukuhara","year":"2022","journal-title":"Cancer Sci"},{"issue":"12","key":"2026081110270967200_bib31","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1038\/s41375-020-1000-0","article-title":"Whole-genome sequencing identifies responders to Pembrolizumab in relapse\/refractory natural-killer\/T cell lymphoma","volume":"34","author":"Lim","year":"2020","journal-title":"Leukemia"},{"issue":"14","key":"2026081110270967200_bib27","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"issue":"14","key":"2026081110270967200_bib28","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2026081110270967200_bib29","first-page":"141","article-title":"Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170","volume":"142","author":"Zinzani","year":"2023","journal-title":"Blood"},{"issue":"12","key":"2026081110270967200_bib30","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s10147-024-02627-8","article-title":"Pembrolizumab in Japanese patients with primary mediastinal large B-cell lymphoma: results from the KEYNOTE-A33 study","volume":"29","author":"Kato","year":"2024","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"2026081110270967200_bib32","doi-asserted-by":"crossref","first-page":"9106","DOI":"10.1038\/s41467-024-53376-1","article-title":"Modeling NK-cell lymphoma in mice reveals its cell-of-origin and microenvironmental changes and identifies therapeutic targets","volume":"15","author":"Koya","year":"2024","journal-title":"Nat Commun"},{"issue":"9","key":"2026081110270967200_bib33","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00277-015-2401-4","article-title":"High numbers of CD68+ tumor-associated macrophages correlate with poor prognosis in extranodal NK\/T-cell lymphoma, nasal type","volume":"94","author":"Wang","year":"2015","journal-title":"Ann Hematol"},{"issue":"6","key":"2026081110270967200_bib34","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"7528","key":"2026081110270967200_bib35","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"5","key":"2026081110270967200_bib36","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1016\/S2352-3026(24)00066-8","article-title":"First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer\/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial","volume":"11","author":"Tian","year":"2024","journal-title":"Lancet Haematol"},{"issue":"5","key":"2026081110270967200_bib37","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2217\/fon-2023-0065","article-title":"Tislelizumab and radiation therapy in low-risk early-stage extranodal natural killer\/T-cell lymphoma, nasal type: a phase II study protocol","volume":"20","author":"Li","year":"2024","journal-title":"Future Oncol"},{"issue":"2","key":"2026081110270967200_bib38","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1182\/blood.2024027109","article-title":"Efficacy of combined CD38 and PD1 inhibition with isatuximab and cemiplimab for relapsed\/refractory NK\/T-cell lymphoma","volume":"146","author":"Kim","year":"2025","journal-title":"Blood"},{"issue":"4","key":"2026081110270967200_bib39","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/bjh.12659","article-title":"Differences in incidence and trends of haematological malignancies in Japan and the United States","volume":"164","author":"Chihara","year":"2014","journal-title":"Br J Haematol"},{"issue":"6371","key":"2026081110270967200_bib40","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"issue":"3","key":"2026081110270967200_bib41","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O'Donnell","year":"2019","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/15\/5276\/2535689\/blooda_adv-2026-019929-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/15\/5276\/2535689\/blooda_adv-2026-019929-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:43:32Z","timestamp":1786463012000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/15\/5276\/568544\/Atezolizumab-for-relapsed-refractory-extranodal-NK"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":41,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026,8,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026019929","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,11]]},"published":{"date-parts":[[2026,7,30]]}}}